Literature DB >> 307006

The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.

B S Coller.   

Abstract

Ristocetin will induce the agglutination of platelets in the presence of von Willebrand factor. In previous studies, an electrostatic mechanism was proposed for this phenomenon wherein first the platelet's surface charge is reduced by the binding of ristocetin and then the von Willebrand factor acts as a bridge between platelets. To test this hypothesis, the effects of ristocetin and von Willebrand factor, singly and together, on the electrophoretic mobility of normal, trypsinized, and Bernard-Soulier platelets was measured. Ristocetin alone, at concentrations of 0.5 mg/ml or more, produced a statistically significant reduction in the electrophoretic mobility of fresh or fixed platelets. Control experiments showed that the reduction was not due to changes in the ionic milieu of the solution. Therefore, the decrease in platelet mobility is evidence for binding of ristocetin to the platelet surface. Bernard-Soulier and trypsinized platelets also had reductions in mobility with ristocetin, suggesting that ristocetin binds to the platelet at sites other than the binding site for von Willebrand factor. The presence of plasma from a patient with von Willebrand's disease did not alter the reduction in mobility of normal platelets by ristocetin. However, the reduction was markedly enhanced in the presence of normal plasma. This enhancement did not occur with Bernard-Soulier platelets and was inhibited by anti-Factor VIII/von Willebrand factor antiserum or trypsinization of the platelets. Thus, the enhanced reduction appears to be associated with the binding of von Willebrand factor to the platelet surface. These studies indicate that platelets undergo two changes with ristocetin and von Willebrand factor, both of which facilitate agglutination: reduction in net surface charge and binding of von Willebrand factor, a large molecule which can serve as a bridge between platelets. In parallel studies, bovine von Willebrand factor, without ristocetin, agglutinated and reduced the electrophoretic mobility of normal but not Bernard-Soulier or trypsinized platelets; this indicates a similar mechanism of agglutination.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 307006      PMCID: PMC372637          DOI: 10.1172/JCI109032

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  On the interaction between ristocetin and the ristocetin cofactor (RCOF).

Authors:  M Floyd; W Burns; D Green
Journal:  Thromb Res       Date:  1977-06       Impact factor: 3.944

2.  Binding of factor VIII to platelets in the presence of ristocetin.

Authors:  M B Zucker; S J Kim; J McPherson; R A Grant
Journal:  Br J Haematol       Date:  1977-04       Impact factor: 6.998

3.  Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity.

Authors:  D Meyer; C S Jenkins; M D Dreyfus; E Fressinaud; M J Larrieu
Journal:  Br J Haematol       Date:  1974-12       Impact factor: 6.998

4.  Ristocetin--a new tool in the investigation of platelet aggregation.

Authors:  M A Howard; B G Firkin
Journal:  Thromb Diath Haemorrh       Date:  1971-10-31

5.  Preparation and platelet aggregating activity of 125I-labeled ristocetin.

Authors:  R F Baugh; J E Brown; C Hougie
Journal:  Anal Biochem       Date:  1977-03       Impact factor: 3.365

6.  Studies on the mechanism of ristocetin-induced platelet aggregation.

Authors:  H E Kattlove; M H Gomez
Journal:  Blood       Date:  1975-01       Impact factor: 22.113

7.  Changes in the electrokinetic properties of platelets during their aggregation.

Authors:  G V Seaman; P S Vassar
Journal:  Arch Biochem Biophys       Date:  1966-10       Impact factor: 4.013

8.  Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.

Authors:  B S Coller; H R Gralnick
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

9.  Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.

Authors:  H J Weiss; J Rogers; H Brand
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  MICROELECTROPHORESIS OF WASHED AND UNWASHED HUMAN BLOOD PLATELETS, WITH ADDITIONAL STUDIES OF PLATELETS FROM PATIENTS WITH VON WILLEBRAND'S DISEASE AND THROMBASTHENIA.

Authors:  M B ZUCKER; R U LEVINE
Journal:  Thromb Diath Haemorrh       Date:  1963-11-01
View more
  6 in total

1.  Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.

Authors:  K J Kao; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

2.  Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G.

Authors:  A Moore; G D Ross; R L Nachman
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

3.  Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Brian R Branchford; Raymond G Hoffmann; Thomas C Abshire; Jorge A Di Paola; W Keith Hoots; Cindy Leissinger; Jeanne M Lusher; Margaret V Ragni; Amy D Shapiro; Robert R Montgomery
Journal:  Blood       Date:  2010-03-15       Impact factor: 22.113

Review 4.  Perioperative management of patients with von Willebrand's disease.

Authors:  C B Cameron; N Kobrinsky
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

5.  Exposure of platelet fibrinogen receptors by ADP and epinephrine.

Authors:  J S Bennett; G Vilaire
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

6.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

Authors:  L De Marco; S S Shapiro
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.